Medtronic Rapid Exchange Stent Systems Require License For U.S. Marketing
This article was originally published in The Gray Sheet
Executive Summary
Medtronic would need to pursue a license agreement with Boston Scientific in order to keep its rapid exchange coronary stent systems on the U.S. market, following an adverse arbitration panel ruling July 18.